LUND, Sweden, March 23, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company's lead asset, mitazalimab. Safety evaluation of the second dose-escalation cohort (900 µg/kg of mitazalimab in combination with mFOLFIRINOX) has concluded, which marks the successful completion of the Phase Ib part of the study. The Data Review Committee has declared the 900 µg/kg mitazalimab dose to be safe and recommended that the dosing level should be continued for the Phase II study. Enrollment for the Phase II has begun and is ongoing at sites in Europe (NCT04888312).
OPTIMIZE-1, an open-label, multi-center Phase Ib/II study is assessing the safety and efficacy of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in patients with metastatic pancreatic ductal adenocarcinoma. First patient was dosed in Q3 2021 (press release). The study's design utilizes mitazalimab's differentiated efficacy and tolerability profile, allowing administration of higher and more frequent doses. This increases the likelihood of demonstrating clinical benefit to patients as a potential first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX.
The interim efficacy readout for OPTIMIZE-1 is expected to be announced in Q4 2022.
"I am happy to report that mitazalimab is safe and tolerable at the highest dose tested in OPTIMIZE-1, especially in combination with chemotherapy like mFOLFIRINOX. This allows us to continue on to the Phase II of OPTIMIZE-1, dosing at 900 µg/kg," comments Søren Bregenholt, CEO of Alligator Bioscience. "We continue to enroll patients as projected and make great progress towards the efficacy read-out planned for later this year."
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit http://www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
SOURCE Alligator Bioscience